Portfolio news 0

Oxford Nanopore Technologies Plc

Oxford Nanopore - London Calling Technology Update

Oxford Nanopore Technologies Plc

Oxford Nanopore strengthens executive leadership team

Microbiotica Ltd

Microbiotica announces positive Results from its Phase 1b Trial (MELODY-1) of MB097, a precision microbiome co-therapy in advanced melanoma

Atisama Therapeutics

Atisama Therapeutics advances RB042 into multiple ascending dose cohorts of Phase 1 trial and appoints Bernard Coulie as Chair of the Board

Atisama Therapeutics

Rage Bio becomes Atisama Therapeutics

Mantle8

Mantle8 raises €31m in Series A funding to prove commercial viability of natural hydrogen production

Artios Pharma

Artios announces clinical trial collaboration with GSK to evaluate Alnodesertib in combination with Risvutatug Rezetecan, a B7-H3-targeted ADC in gastrointestinal tumors

Enterprise Therapeutics

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

Quantum Motion Technologies

Quantum Motion Raises $160m Series C to Deliver Quantum Computing’s “Transistor Moment”

Ionix Advanced Technologies Ltd

Ionix’s sensing system the world’s most demanding industries rely on – HotSense – receives a King’s Award for Enterprise for Innovation